Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer

Loading...
Thumbnail Image

Authors

Rapoport, Bernardo Leon
Theron, Annette J.
Vorobiof, Daniel A.
Langenhoven, Lizanne
Hall, Jacqueline M.
Van Eeden, Ronwyn I.
Smit, Teresa
Chan, Sze-Wai
Botha, Michael C.
Raats, Johann I.

Journal Title

Journal ISSN

Volume Title

Publisher

MDPI

Abstract

AIM: We investigated the prognostic potential of pretherapy measurement of the neutrophil/lymphocyte ratio (NLR) in patients (n = 56) with non-small-cell lung cancer deemed suitable for treatment with nivolumab. MATERIALS & METHODS: This was a multicenter, noninterventional, retrospective data analysis, involving five oncology centers. RESULTS: Patients with prenivolumab NLR values of <5 and ≥5 had respective median overall survival (OS) values of 14.5 and 7.02 months (p = 0.0026). Patients with ≤2 and >2 metastatic sites had median OS values of 11.4 and 6.1 months, respectively (p = 0.0174). A Cox multiple regression model revealed baseline NLR ≥5 as the only variable significantly associated with decreased OS (p < 0.0447). CONCLUSION: Pretreatment elevated NLR values are associated with poor outcomes in patients with recurrent metastatic non-small-cell lung cancer treated with nivolumab.

Description

Keywords

Nivolumab, PD-1 inhibitor, Pretherapy measurement, Neutrophil/lymphocyte ratio (NLR), Non-small cell lung cancer (NSCLC)

Sustainable Development Goals

Citation

Rapoport, B.L., Theron, A.J., Vorobiof, D.A., et al. 2020, ' Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer', Lung Cancer Management, vol. 9, no. 3, art. LMT37, pp. 1-12.